![]() ![]() However, an agent that should improve both endothelial dysfunction and associated dementia still need to be explored. Cholinesterase inhibitors, calcium channel blockers and glutamate antagonists are few classes of pharmacological agents which are being clinically explored to reduce symptomatically the impact of cognitive dysfunction associated with vascular dementia. Only limited therapeutic interventions are available to reduce the incidence of dementia due to decline of learning and memory of individuals. Hence, experimental studies and treatment approaches focused on drugs that increase levels of acetylcholine in the brain to compensate for losses of cholinergic function of the brain. Although there are several neuronal pathways and neurotransmitters were involved in the process of learning and memory and on the basis of experimental as well as clinical evidences, central cholinergic system is considered as the most important neurotransmission system which is involved in regulation of cognitive functions. Amnesia is mainly characterized by loss of memory ability sufficiently and interferes with one’s occupational or social activities and it is one of the common causes which leads to a condition called dementia which is a progressive neurodegenerative disorder associated with loss of neurons in distinct brain areas. Memory is one of the vital ability of an individuals to record events, preserve information and retain them over short and long periods. Rosuvastatin, learning and memory, elevated plus maze, morris water maze, scopolamine Introduction In MWM test, rosuvastatin treatment showed significant decrease in escape latency period (p<0.05) when compared to scopolamine treated animals The results confirm that, scopolamine impaired learning and memory process in animals, whereas administration of ROSS significantly ameliorated scopolamine induced amnesia in both elevated plus maze and Morris water maze test as indicated by significant reduction (p<0.05) in transfer latency (TL) (p<0.05) and escape latency (EL) respectively, hence it can be concluded that, that rosuvastatin improves cognitive functions against scopolamine-induced amnesia in mice. Whereas piracetam and rosuvastatin received animals showed significant decrease (p<0.05) in transfer latency period when compared to scopolamine treated animals. In EPM model, scopolamine received animals showed significant increase in transfer latency on day 7 and 14 when compared to control animals. Cognitive skills of the animals were examined after the induction of amnesia by using elevated plus maze (EPM), Morris water maze (MWM). Experiments were carried out on 20 adult albino mice, divided into 4 groups and the experimental animals were treated for 14 days with ROSS (10mg/kg.p.o).To induce amnesia, scopolamine 3 mg/kg ip was administered intraperitoneally. The present study was undertaken to investigate the effects of rosuvastatin (ROSS) on learning and memory on scopolamine (SCOP) induced amnesia in mice.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |